AstraZeneca completes delivery of 61 million COVID-19 vaccine doses to Thailand

More than 15 million doses of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) were delivered to Thailand’s Ministry of Public Health in December, to complete an initial commitment of 61 million.

Another 60 million doses of COVID-19 Vaccine AstraZeneca will be supplied to Thailand across 2022, based on an agreement made between AstraZeneca and the government in September of this year.

James Teague, Country President, AstraZeneca (Thailand) Ltd., said: “Supporting the Ministry of Public Health’s mass vaccination programme via the production and supply of our vaccine is our highest priority, and has gained urgency following the emergence of the new Omicron variant. We have been able to accelerate our supply over the last quarter and will continue to support Thailand in meeting the dynamic challenges of the pandemic.”

COVID-19 Vaccine AstraZeneca manufactured in Thailand has been authorised under the World Health Organization (WHO) Emergency Use Listing (EUL) procedure. The authorisation recognises that vaccine doses manufactured by Siam Bioscience, AstraZeneca’s production partner in Thailand, is the same product as COVID-19 Vaccine AstraZeneca manufactured elsewhere in the world.

To date, more than 2.3 billion doses of Oxford-AstraZeneca COVID-19 have been supplied to over 170 countries, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries. The vaccine is estimated to have helped prevent 50 million COVID-19 infections, five million hospitalisations and helped save more than one million lives due to COVID-19. From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.

COVID-19 Vaccine AstraZeneca
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.